SV Health Investors — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
RejuvenAir, developed by CSA Medical, is a bronchoscopic cryosurgical device that sprays metered doses of liquid nitrogen to destroy damaged airway cells and treat the underlying cause of COPD with Chronic Bronchitis.
HealthtechMedical DevicesLutherville, US
Vincent Owens(Director)Ellen Sheets(Executive Officer, Director)Richard Kent(Director)Thomas Snead(Director)Ian J. Vawter(Executive Officer)
BoardTracy Marshbanks(Director)
Board seatPaul LaViolette· per SEC Form D
AdvanCell develops radioisotope-based therapies, using Th-228 sourced through the U.S.
BiotechHealthtechMedical DevicesCambridge, US
Philina Lee(Executive Officer, Director)Aaron Pickett(Executive Officer)Wing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)Jamil Beg(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.